Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026
The Company is transitioning its year-end from March 31st to December 31st
Announced revenue guidance of $8 million for the year ending December 31, 2026 which represents approximately 15% growth; and $16-$18 million or more than 110% growth for the year ending December 31, 2027
Conference call at 8:00 a.m. ET today, June 26th
GARDEN CITY, N.Y., June 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced its financial results for the fiscal fourth quarter and year ended March 31, 2026, and provided a corporate update.
"Fiscal 2026 was a year of meaningful transition for Beyond Air, marked by significant progress in strengthening the foundation of our LungFit PH commercial program," said Robert Goodman, Chief Executive Officer of Beyond Air. "Since being appointed CEO, I have focused on sharpening our commercial execution while aligning our R&D efforts and operating resources with the opportunities we believe can create the greatest shareholder value. Our fiscal 2026 performance, including the 107% revenue growth, strong customer retention of over 90% and new hospital customer wins, reflect that focus and positions us for what we believe could be an important inflection point for the business."
"We are encouraged by the market interest in the second-generation LungFit PH system, which is currently under FDA review," continued Mr. Goodman. "Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground. If approved, we believe the addressable market opportunity for the LungFit platform could increase by 4X in the United States to approximately $400 million, and to more than $1 billion worldwide," concluded Mr. Goodman.
Recent Financial and Operating Highlights:
Revenue increased 107% to $7.7 million for the fiscal year ended March 31, 2026, compared with $3.7 million for the fiscal year ended March 31, 2025. The growth was driven by increased demand for LungFit PH in both the U.S. and international markets.
Revenue increased 66% to $1.9 million for the fiscal quarter ended March 31, 2026, compared with $1.2 million for the same period last year.
Awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO), marking the third major U.S. GPO to engage Beyond Air and significantly expanding the Company's access to a broad network of healthcare providers.
Expanded the global distribution network for LungFit PH throughout fiscal year 2026, which now covers more than 45 countries positioning the Company for continued international commercial expansion, subject to applicable regulatory approvals.
Robert Goodman was appointed as Chief Executive Officer in March 2026 and will continue to serve on the Company's board of directors. Mr. Goodman is a seasoned healthcare executive and board member with a distinguished track record of leadership across the life sciences industry.
Dan Moorhead was appointed as Chief Financial Officer in January 2026. Mr. Moorhead has more than 20 years of finance leadership experience across both public and private companies.
Bob Carey assumed the role of Chairman of the Board, reflecting the Board's continued focus on strengthening governance and supporting the Company's next phase of commercial and strategic growth.
Nasdaq granted the Company's request to continue listing on The Nasdaq Stock Market, subject to regaining compliance with Nasdaq Stock Market LLC's Listing Rule 5550(a)(2) (the "Bid Price Rule") by July 31, 2026. Following stockholder approval at the Company's June 18 special meeting, the Board approved a 1-for-20 reverse stock split, which is expected to enable the Company to regain compliance ahead of the deadline.